Stock Split Watch: Is Moderna Next?

Moderna's stock has surged 650% in 2026 following a turnaround driven by cost-cutting and focus on oncology and rare disease candidates. While the biotech's personalized cancer vaccine shows promise with strong phase 3 melanoma trial results, the article suggests a stock split may not be imminent, as the current price remains accessible to investors and the company has significant growth catalysts ahead.